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Exploring copper(I)- and ruthenium(II)-catalyzed azide-alkyne cycloadditions and a Sonogashira 
protocol, novel cytostatic ferrocene-cinchona hybrids were synthetized displaying significant in 
vitro activity on HEPG-2 and HT-29 cells. Preliminary SAR studies disclosed that compounds 
incorporating linkers with 1,2,3-triazole and chalchone residues can be considered as promising 
lead structures. According to the best of our knowledge this is the ﬁrst report on the 
incorporation of ferrocene nucleus in the reputed cinchona family via triazole and chalcone 
linkers with established pharmaceutical proﬁle. 









It is a generally accepted view that chemotherapy is one of the 
essential tools for treatment of malignancies. However, cisplatin, 
one of the most commonly used chemotherapeutics in the 
treatment of cancer
1
 capable of covalently binding to DNA,
2
 
causes severe side-eﬀects.3 In order to overcome the toxic 
limitations and to broaden the set of treatable malignancies, an 
intense search was initiated for alternative agents with 
remarkable structural diversity and led to the development of 
carboplatin and oxaliplatin, the further emblematic 
representatives of clinically approved classical metal-complexes,
4
 
and a wide variety of organometallic and organic potential 
cytostatic agents. Among organometallics, due to their nontoxic 
character and chemical stability, ferrocene derivatives with 
diverse molecular architectures are of pronounced importance. A 
concept taken into account for the design of compounds was that 
replacement of an aromatic nucleus of certain organic 
compounds for a three-dimensional ferrocene unit with tuneable 
redox character can lead to products possessing unexpected 
properties which are absent or less manifested in the parent 
molecule. This view was supported by a number of reviewed 
examples
5
 including ferrocene-containing analogues of the non-
steroidal selective estrogen receptor modulator 
hydroxytamoxifen
6
 which display strong cytotoxic and cytostatic 
effects on hormone-independent MDA-MB-231 breast tumour 
cells. 
Chalcones represent a privileged molecular fragment having a 
number of interesting biological properties such as antioxidant, 
cytotoxic, anticancer, antimicrobial, antiprotozoal, antiulcer, 
antihistaminic and anti-inflammatory activities.
7
 There are also 
remarkable examples of active metallocene derivatives with 
chalcone analogue structures. For instance, ferrocenylprop-2-en-
1-ones were also demonstrated to strongly inhibit the HepG2 




The potential of simple ferrocene-based heterocycles in 
fighting cancer,ferrocenylalkyl-substituted azoles were also 
found to exhibit in vivo antitumor activity presenting up to 100% 
of tumour growth inhibition associated with lower toxicity when 
compared to clinically used drugs.
9
 In this regard, even metal-
free organic 1,4-disubstituted 1,2,3-triazoles exhibit significant 
antiproliferative effect against a wide range of human malignant 
cell lines.
10
 On the other hand, 1,5-disubstituted 1,2,3-triazole 
analogues of combretastatin A-4 were also found to display 
marked cytotoxicity on several cancer cell lines.
11
 
 The structural versatility of deserving therapeutic agents is 
further demonstrated by several members of natural alkaloids 
including vinblastine, camptothecine, staurosporine and 
ellipticin.
12
 It is also well-documented that the application of 
quinine derivatives in the field of cancer diagnosis
13
 and in 
chemotherapy
14
 goes far back to the past. Accordingly, we have 
also prepared cinchona-ferrocene conjugates with amide and urea 
spacers displaying significant in vitro activity against MCF-7 
breast adenocarcinoma, HepG2 hepatoma, HL-60 leukemia and 
SH-SY5Y neuroblastoma human cell cultures characterized by 
IC50 values in the range of 0.1-4.2 M concentrations.
15
 It must 
be pointed out here that alkaloid chemistry utilizing click strategy 
seems to have a real potential in searching novel lead structures 
as demonstrated by the significant in vitro antiproliferative 
effects of cinchona hybrids with 1,4-disubstituted 1,2,3-triazole 
linker containing nucleoside
10a
 or polyether residue.
10b
 
Taking all of the aforementioned precedence into account, on 
the basis of the concept of fragment-based drug design
16 
we 
envisaged the synthesis of novel hybrids of enhanced activity by 
reasonable chemical combination of modules having themselves 
well-documented anticancer effects providing a possibility for a 
synergic mode of action on appropriate biological targets. Thus, 
here we report on the synthesis, brief structural characterization 
and in vitro evaluation of the first representatives of ferrocene-
cinchona hybrids tethered via chalcone- and 1,2,3-triazole 
moieties along with seven chalcone-free triazole derivatives and 
a chalcone- and triazole-free alkyne serving as reference 
molecules to establish preliminary structure-activity 
relationships. 
The synthetic pathway leading to fundamental target 
structures incorporating the entire set of the envisaged building 
blocks is terminated by the widely used copper(I)-mediated 
regioselective Sharpless [2+3] cycloaddition,
17
 involving the 
readily available diastereomeric cinchona-derived alkynes 1a,b 
and ferrocene-containing azido components 2 and 3 (Scheme 1) 
prepared by base-mediated condensation of acetylferrocene with 
the corresponding azidobenzaldehyde (For experimental details: 
cf. Supporting information). 
(To be inserted here) 
Scheme 1.Synthesis of the targeted ferrocene-cinchona hybrids. 
 
The reactions of alkynes 1a,b
18
 with azide components 2 and 
3, respectively, conducted in H2O/n-BuOH (1:1, v/v) for 10 h at 
room temperature in the presence of low catalyst loading (1 
mol% of CuSO4, 5 mol% of Na-ascorbate) (Method i.) afforded 
mixtures of diastereomers, which were separated (isolated yields: 
23/51% for4a/4c; 21/39% for4b/4d; 23/48% for5a/5c; and 
29/44% for 5b/5d) with significant dominance of the epimerized 
products stabilized by intramolecular hydrogen bridge between 
the hydroxyl group and the quinuclidene N1-atom.
19
 The partial 
epimerization of C9 sterogenic center in the cinchona residue 
takes probably place via reversible deprotonation enabled by the 
coordination of Cu(I)-species to quinoline N1-atom. Supporting 
this view, a higher catalyst loading (4 mol% of CuSO4) even with 
a shorter reaction time (2 h) (Method ii) gave rise to increase in 
both conversion and epimerization (isolated yields: 12/82% for 
4a/4c; 23/54% for 4b/4d; 17/80% for 5a/5c; and 24/69% for 
5b/5d).  
In order to obtain further hybrids with complete set of the 
envisaged building blocks including 1,5-disubstituted 1,2,3-
triazole fragment, we performed click reactions of 1a,b and 2 
using complex Cp*RuCl(1,5-COD) as catalyst (Method iii: 
Scheme 1).
20
 Both reactions proceeded with concomitant Ru(II)-
mediated C9-epimerization resulting in the corresponding 
cinchona product in reasonable yields (46% for 6c and 57% for 
6d). The facile epimerization accompanying cycloadditions 
might again be interpreted in terms of coordination between 
metal-containing species and the quinoline N1-atom. Besides 
hybrids 6c,d aminochalchone 7, resulted from the reduction of 
the azide component 2, was also formed under the applied 
conditions and could be isolated in low yield (16-28%). We also 
attempted to couple 1a,b and 2 in dioxane at 80 
o
C in the 
presence of complex Cp*RuCl(PPh3)2 (Method iv). While the 
reaction of 1b afforded 6d in low yield (22%) along with a 
substantial amount of 7 (35%), under the same conditions 1a 
proved to be almost completely resistant to ruthenium-catalysis 
and the reaction led to the isolation of 7 in mediocre yield (45%). 
Cinchona hybrid 6c could only be detected by 
1
H-NMR in traces 
in the crude product. These findings suggest that – strongly 
depending on the nature of the spectator ligands – 9-OH group 
might coordinate to the Ru(II)-centre to form the catalytically 
active site which can be docked in the proximity of the alkyne 
residue in the complex derived from 1b, but in the diastereomeric 
counterpart derived from 1a, being spatially separated from the 
ethinyl group, the hydroxyl-coordinated metal centre is not 
capable of catalysing the click reaction. This view can be 
considered to be in line with the formation of 7 accompanying 
[2+3] cycloadditions effected by Ru(II)-catalysed azide-
reduction
21
 which probably involves the cinchona component as a 
carbinol-based reducing agent being converted into the alkyne 
analogue of quininone or quinidinone,
22
 however, the isolation 
and identification of these ketones have failed so far.  
The copper-mediated [2+3] cycloaddition of azidoferrocene 
(8), azidomethylferrocene (9) and 1,1’-bis(azidomethyl)ferrocene 
(10) with alkynes 1a,b conducted under the conditions of Method 
i resulted in the formation of a set of triazoles of types 12-15 as 
chalchone-free models. In spite of the low catalyst loading, the 
majority of these click reactions afforded triazole-tethered 
hybrids in mediocre yields (78% for 12c; 87% for 13d and 64% 
for 14d along with azidomethyl compound 15d in low yield 
(16%)), each of them incorporating cinchona residue with 
reversed configuration at the C9 stereogenic center. On the other 
hand, besides 13c with reversed C9-configuration, a small 
amount of its epimer (13a) with retained C9-configuration could 
also be isolated from the reaction mixture (yields: 15/65% for 
13a/13c). The relative stability of the epimers reflected from the 
stereochemical outcome of the click reactions was also supported 
by comparative DFT calculations carried out on reasonably 
simplified models (cf. Supporting information). To our best 
knowledge, the copper- and ruthenium-mediated reactions 
discussed in this contribution are the first examples of transition-
metal catalyzed C9-epimerization of cinchona derivatives which 
can be utilized in related synthetic chemistry. 
By means of a Sonogashira protocol, employing DIEA as 
solvent along with catalyst system composed of CuI (2 mol%) 
and PdCl2(PPh3)2 (5 mol%) (Method iii), 1b and iodoferrocene 
11 were coupled to give the alkyne-tethered hybrid 16b, a further 
reference model, in reasonable yield (76%). Probably due to the 
use of amine solvent preventing Cu(I)-species to coordinate to 
quinoline N1-atom, the formation of 16b was not accompanied 
by C9-epimerization. 




C-NMR data of the novel 
compounds listed in the Supporting information are consistent 
with their structure, only the following remarks about the 
discrimination between the diastereomeric pairs of types a/c and 
b/d are necessary to make. Indicating its endo orientation in 
compounds type c, proton H9 is involved in NOESY correlations 
with quinuclidine protons H5-, H6-, and H7, while the 
NOESY spectra of diastereomers type a reveal correlation 
between H9 and H6, but do not show interaction between 
proton pairs H9/H5and H9/H7, respectively. Accordingly, the 
approximate endo orientation of the hydroxyl group in 
compounds type a is reflected from the signals of the proximal 
quinuclidine protons H5-, H6- and H7downfield- shifted by 
0.2-0.6 ppm relative to those measured for compounds type c.  
Due to the anisotropic effect of the proximal hydroxyl group, 
in the 
1
H NMR spectra of 4b and 5b the signal of H2A and 
H7protons are downfield-shiftedby ca. 0.1-0.2 ppm relative to 
those measured for their epimers 4d and 5d, in which the 
hydroxyl group is anchored in a five-membered chelate ring by a 
hydrogen bond to the quinuclidine N1-atom. Accordingly, in 
compounds 4d, 5d, 6d, 12d, 13d, 14d and 15d characteristic 
NOE was detected between proton pair H9/H7. 
We have determined the in vitro cytostatic activity of the 
novel hybrids expressed as IC50values on HepG2 hepatoma and 
HT-29 colorectal adenocarcinoma human tumor cell cultures. 





concentration range and the viability was determined by MTT-
assay. 
Table 1. In vitro cytostatic effect of the compounds expressed as 
IC50 values±SD [µM]. 
 HepG2 HT-29 
4a  5.5±1.4 5.3±1.6 
4b  14.3±14.5  3.9±0.2 
4c  4.3±0.4 5.6±1.6  
4d  9.9±0.5 4.5±6.5 
5a 4.1±1.9 4.4±1.9 
5b  3.4±0.4 2.5±1.3 
5c  6.1±3.3 4.1±0.1 










13a 52.8±15.8 17.3±5.9 
13c  64.8±10.1 20.8±1.1 
13d  64.8±10.1 79.4±4.5 
14d  22.8±3.3 25.3±10.0 
15d  69.9±1.3 23.5±0.6 
16b 17.7±9.0 18.3±2.0 







1a >100 >100 
1b >100 >100 
Tamoxifen 20.0±6.5 15.6±5.7 
 
The data summarised in Table 1 show that, irrespective of the 
relative configuration at positions 8 and 9 and on the substitution 
pattern of the phenyl ring attached to thetriazolyl-cinchona 
module, compounds comprising the entire selection of modules 
(4a,c, 5ad, 6c,d) produced characteristic and pronounced in 
vitro cytostatic effect on both cellcultures studied 
(IC50=0.7±0.16.7±7.7 µM), exceeding the activity of Tamoxifen 
used as reference. It is interesting to note, that, quinidine and 9-
epiquinidine derivatives 4b and 4d with 1,2-disubstituted 
benzene ring displayed similar level of activity on HT-29 cells 
(IC50=3.9±0.2 and 4.5±6.5 µM, respectively) but these 
compounds exhibited somewhat less marked effect against 
HepG2 cell culture (IC50=14.3±14.5 and 9.9±0.5 µM, 
respectively). On the other hand, 6c and 6d, the epiquinine and 
epiquinidine-based models comprising 1,2-disubstituted benzene 
ring and 1,5-disubstituted 1,2,3-triazoles moiety were found to 
display comparable activity against both investigated cell 
cultures. It must also be emphasized that the latter diasteromer 
with epiquinidine fragment (6d) seems to be most promising 
hybrid in the group of models comprising the entire set of the 
envisaged building blocks (IC50=0.7±0.1 and 1.5±0.2 µM, for 
HEPG2 and HT-29, respectively). 
Highlighting a significant contribution of the chalcone 
fragment to cytostatic effect, except for the slightly deactivated 
bis-triazole derivative 14d with C2-symmetry, the majority of 
ferrocenyl- and ferrocenylmethyltriazoles of types 12-15 
displayed considerably decreased in vitro antitumor effect on 
HEPG2 cells (IC50=52.8±15.873.5±1.3 µM). On the other 
hand, the activities of 12c, 13a,c, 14d and 15d were less 
pronounced against HT-29 cells relative to those measured for 
chalcones 4a-d and 5a-d (IC50=17.3±5.925.3±10.0 µM). It is 
worth to note that the sluggish activity of 13d was significantly 
enhanced by introduction of a further triazolylmethyl group into 
the 
5
-Cp ring of the organometallic fragment to obtain 14d. The 
assay carried out with precursors 2 and 3 revealed the importance 
of the relative position of azido group and the enone fragment in 
terms of in vitro activity: 2 exhibited pronounced effect on both 
cell cultures, while its regioisomer 3 with spatially separated 
functional groups displayed a modest activity on HT-29 cells and 
proved to be essentially inactive on HEPG2 cells. This difference 
in activity might be attributed to azide-decomposition processes 
assisted by the proximal carbon-carbon double bond to generate 
nitrene-derived species including amine 7 with significant 
activity presented under the conditions of in vitro tests 
(IC50=15.8±0.8 and 5.8±0.3 µM, for HEPG2 and HT-29, 
respectively). We also observed that contrary to inactive terminal 
alkynes 1a,b (IC50>100 µM) ferrocenylalkyne 16b exhibited 
comparable effect with Tamoxifen, used as reference compound, 
against both cell lines investigated. 
Taken together, this contribution indicates that the concept of 
fragment-based drug design seems to be applicable for the 
development of hybrids incorporating chalcone, ferrocene, 1,2,3-
triazole and cinchona modules in the proposed molecular 
architectures. In this regard it is also important to mention that in 
preliminary studies hybrids 4a-d proved to be highly active 
against MDR cancer stem cell lines.
21
 We also disclosed structure 
activity relationship data (SAR) demonstrating the importance of 
chalcone moiety as well as the cytostatic effect of an alkyne-
tethered ferrocene-cinchona hybrid (16b). The surprising in vitro 
activity of (E)-3-(2-azidophenyl)-1-(ferrocenyl)prop-2-en-1-one 
(2), characterized by pronounced dependence on substitution 
pattern, might initiate a conceptually novel approach in the 
search for a novel class of active molecules. Considering the 
findings presented here we extend systematically the group of 
modular hybrids and carry out further SAR studies including 
cellular uptake studies and mechanistic investigation of possible 

























Scheme 1.Synthesis of the targeted ferrocene-cinchona hybrids. 
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